DUBLIN — Research and Markets has announced the release of “Dental Pain – Pipeline Review, H1 2013,” a report that provides information on the therapeutic development for dental pain, complete with latest updates and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for dental pain.
The scope of the report includes:
– A snapshot of the global therapeutic scenario for Dental Pain.
– A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.
Companies Involved in Dental Pain Therapeutics Development:
– Novartis AG
– Pfizer Inc.
– IBSA Institut Biochimique SA
– NeuroDiscovery Ltd
– Array BioPharma Inc.
Drug Profiles:
– ARRY-797
– NSL-101
– diclofenac sodium
– SAF-312-A
– PF-05089771
– 29B-S
– 18c-S
– 34B-S
For more information visit https://www.researchandmarkets.com/research/8bzm96/dental_pain.
